Jim Cramer's Stop Trading: GILD KORS

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, looked at shares of Gilead Sciences (GILD). 

Wells Fargo said Gilead's Hepatitis C drug, Solvadi, will do better than expected. That research note gave  shares a slight boost on Tuesday and could help reverse the stock, which has declined precipitously since March, Cramer said. 

Getting long Gilead Sciences is not "a fool's errand" and growth stocks may be beginning to stabilize at current levels, he added.

Turning to Michael Kors (KORS), he was "a little nervous" about a rally higher from current levels. 

While he admitted to liking Michael Kors, Cramer said there is a "tug of war" between bulls and bears, making it difficult to interpret which way the stock will go. 

He said the company's lack of disclosure and clarity is not helping the situation, as pointed out by TheStreet's Herb Greenberg.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook